Do you need to be severely obese to qualify for GLP-1 drugs?

What's this video probably claiming?

Based on the caption and hashtags, this creator is pushing back on the idea that GLP-1 receptor agonists like tirzepatide are only for people with extreme obesity. The framing, "you don't have to be HUGEEEEE," suggests she's addressing the gatekeeping narrative that circulates both in clinical settings and online, where people with lower BMIs report being denied prescriptions or shamed for using these drugs. Down 30 pounds on her tirzepatide journey, she's likely sharing her own experience as evidence that GLP-1s can be appropriate for people who aren't at the highest weight categories. This kind of content lands in the GLP-1 community because the eligibility conversation is genuinely murky, and a lot of people feel excluded from treatment they believe could help them. The claim is part personal testimony, part policy argument. Both deserve scrutiny.

What does the science actually show?

The FDA-approved indications for tirzepatide (Zepbound) for chronic weight management require a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or obstructive sleep apnea. That threshold was set based on the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), where participants averaged a BMI around 38 and achieved up to 22.5% body weight loss on 15mg weekly tirzepatide versus 2.5% on placebo. The FDA indications weren't arbitrary. They reflect where the benefit-risk math was actually studied. There is no large randomized controlled trial examining tirzepatide in people with BMIs between 23 and 26 for weight loss alone. Semaglutide (Wegovy) carries the same 30/27 BMI threshold, established through the STEP trials (Wilding et al., 2021, NEJM). Off-label use at lower BMIs does happen, but the evidence base for that population is thin.

Where does the social media noise diverge from clinical reality?

TikTok's GLP-1 community has largely reframed these drugs as accessible tools for anyone wanting to lose weight, regardless of clinical starting point. That's a significant departure from the trial data, which was built around people with genuine metabolic burden. The video's hashtag strategy, tirzepatidejourney and glp1community, plugs into a content ecosystem where personal results routinely substitute for population-level evidence. The problem isn't that the creator is lying. It's that individual success stories at lower weights don't tell us about side effect profiles, cardiovascular outcomes, or long-term safety in that subgroup. Gastrointestinal adverse events affected roughly 40 to 80 percent of SURMOUNT-1 participants depending on dose, and those participants had significant comorbidities that shifted the benefit-risk calculus. For someone with a BMI of 28 and no comorbidities, that tradeoff looks different, and no major trial has worked through it systematically.

What should you actually know?

If your BMI is 27 or higher and you have a qualifying comorbidity, tirzepatide is FDA-approved for you, and the data supporting its use is genuinely strong. If you're below that threshold, you are in off-label territory, and your prescriber is making a judgment call without strong trial evidence behind it. That's not automatically wrong, doctors make off-label decisions every day, but it means you and your doctor are working from extrapolated data, not direct evidence. Telehealth platforms prescribing to anyone who asks, regardless of BMI or comorbidity status, are operating outside the evidence base these drugs were built on. The creator's broader point, that you don't have to be at the highest weight categories to struggle with your health or to benefit from medical support, is fair. But "benefit from medical support" and "should be prescribed a GLP-1" are not the same sentence.